Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - tolvaptan
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp2fe9007bb20986bb15e710aca341907a
identifier: http://ema.europa.eu/identifier
/EU/1/23/1719/001-012
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tolvaptan Accord 7.5 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-2fe9007bb20986bb15e710aca341907a
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/23/1719/001-012
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tolvaptan
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Tolvaptan Accord, which contains the active substance tolvaptan, belongs to a group of medicines called vasopressin antagonists. Vasopressin is a hormone that helps prevent the loss of water from the body by reducing urine output. Antagonist means that it prevents vasopressin having its effect on water retention. This leads to a reduction in the amount of water in the body by increasing urine production and as a result it increases the level or concentration of sodium in your blood.
Tolvaptan Accord is used to treat low serum sodium levels in adults. You have been prescribed this medicine because you have a lowered sodium level in your blood as a result of a disease called syndrome of inappropriate antidiuretic hormone secretion (SIADH) where the kidneys retain too much water. This disease causes an inappropriate production of the hormone vasopressin which has caused the sodium levels in your blood to get too low (hyponatremia). That can lead to difficulties in concentration and memory, or in keeping your balance.
Do not take Tolvaptan Accord
Warnings and precautions Talk to your doctor or pharmacist before taking Tolvaptan Accord:
Drinking enough water Tolvaptan Accord causes water loss because it increases your urine production. This water loss may result in side effects such as dry mouth and thirst or even more severe side effects like kidney problems (see Section 4). It is therefore important that you have access to water and that you are able to drink sufficient amounts when you feel thirsty.
Children and adolescents Tolvaptan Accord is not suitable for children and adolescents (under age 18).
Other medicines and Tolvaptan Accord Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes all medicines obtained without a prescription.
The following medicines may increase the effect of this medicine:
The following medicines may lower the effect of this medicine:
This medicine may increase the effect of the following medicines:
This medicine may lower the effect of the following medicines:
It may still be alright for you to take these medicines and Tolvaptan Accord together. Your doctor will be able to decide what is suitable for you.
Tolvaptan Accord with food and drink Avoid drinking grapefruit juice when taking Tolvaptan Accord.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take this medicine if you are pregnant or breast-feeding.
Adequate contraceptive measures must be used during use of this medicine.
Driving and using machines Tolvaptan Accord is unlikely to adversely affect your ability to drive or to operate machinery. However, you may occasionally feel dizzy or weak or you may faint for a short period.
Tolvaptan Accord contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
If you take more Tolvaptan Accord than you should If you have taken more tablets than your prescribed dose, drink plenty of water and contact your doctor or your local hospital immediately. Remember to take the medicine pack with you so that it is clear what you have taken.
If you forget to take Tolvaptan Accord If you forget to take your medicine, you have to take the dose as soon as you remember on the same day. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for a forgotten dose.
If you stop taking Tolvaptan Accord If you stop taking Tolvaptan Accord this may lead to reoccurrence of your low sodium. Therefore, you should only stop taking Tolvaptan Accord if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any of the following side effects, you may need urgent medical attention. Stop taking Tolvaptan Accord and immediately contact a doctor or go to the nearest hospital if you:
Consult your doctor if symptoms of fatigue, loss of appetite, right upper abdominal discomfort, dark urine or jaundice (yellowing of skin or eyes) occur.
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (cannot be estimated from the available data)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Tolvaptan Accord contains
What Tolvaptan Accord looks like and contents of the pack
Tolvaptan Accord 7.5 mg: Light blue to blue coloured, round, biconvex, uncoated tablets, debossed with "MT" on one side and "18" on other side with approximate dimension of 5.0 mm. Tolvaptan Accord 15 mg: Light blue to blue coloured, triangle, biconvex, uncoated tablets, debossed with '"MT" on one side and "7" on other side with approximate dimension of 6.7 x 6.3 x 3.3 mm. Tolvaptan Accord 30 mg: Light blue to blue coloured, round, biconvex, uncoated tablets, debossed with "MT" on one side and "8" on other side with approximate dimension of 8.1 mm.
Tolvaptan Accord 7.5/15/30 mg tablets are available as 7x1, 10x1, 28x1, 30x1 tablet in perforated unit dose PVC/Alu blisters in a carton.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Accord Healthcare S.L.U. World Trade Center, Moll de Barcelona, s/n, Edifici Est, 6a Planta, 08039 Barcelona, Spain
Manufacturer Accord Healthcare Polska Sp. z.o.o. ul.Lutomierska 50, 95-200, Pabianice, Poland
Pharmadox Healthcare Limited KW20A Kordin Industrial Park, Paola PLA 3000, Malta
Accord Healthcare B.V. Winthontlaan 200,
3526 KV Utrecht, Netherlands
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Entry 1 - fullUrl = Composition/composition-en-2fe9007bb20986bb15e710aca341907a
Resource Composition:
Generated Narrative: Composition composition-en-2fe9007bb20986bb15e710aca341907a
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/23/1719/001-012status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tolvaptan
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp2fe9007bb20986bb15e710aca341907a
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp2fe9007bb20986bb15e710aca341907a
identifier:
http://ema.europa.eu/identifier
/EU/1/23/1719/001-012type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tolvaptan Accord 7.5 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en